Beyond oncology immunotherapy, multiple translational approaches are converging on improved targeting and resistance reversal. A study engineered RuPHOTACs—light-activated PROTACs using red light—aimed at turning protein degraders on only where needed to reduce off-target effects in healthy tissue. Separately, a review and platform work describes antibody-oligonucleotide conjugates for broader targeted gene modulation beyond liver-only delivery. These developments share an operational goal: precision where payload activation or cellular delivery is constrained by biological context. The reports collectively emphasize controllable activation and better intracellular navigation as key barriers to translate otherwise potent molecular tools.
Get the Daily Brief